Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Today’s U.S. healthcare providers face a three-pronged deluge of demands from patients, insurance companies, and the government. To successfully address these new and evolving expectations, members of the medical sector must leverage the capabilities of new wireless technologies – or fall behind their more savvy competitors.
Frost & Sullivan recently published a whitepaper, Mobile Devices and Healthcare: What’s New, What Fits, and How Do You Decide?, which examines the strengths and drawbacks of four major mobile device types – smartphones, tablets, push-to-talk communication devices, and machine-to-machine (M2M) remote medical monitoring devices. Each device category is evaluated for application in three unique environments – the hospital, physician’s office, and the patient’s home. Criteria for selecting a mobility partner are also discussed.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/frostsullivan/51532/
Demo de locutor ingles britanico Edward Olive de un cuento infantil App de dibujos animados para Iphone, Ipad, Android y tablets.
http://www.edwardolive.com/audio-locutor-ingles-madrid-espana-english-british-voiceover-spain1.php
Edward Olive video corporativo locutor ingles britanico Madrid España con estudio propio autonnomo
Corporate video voiceover by Edward Olive freelance self employed voice-over actor in Madrid Spain with home studio
http://www.edwardolive.com/audio-locutor-ingles-madrid-espana-english-british-voiceover-spain1.php
The Tween Internet Safety Survey, commissioned by Cox Communications in partnership with the National Center for Missing & Exploited Children (NCMEC), found that nearly all tweens (95 percent) use mobile devices to go online.
Mobile devices and gaming consoles are widely used by tweens to access web content, and the survey revealed a lack of guidelines and controls on these devices that can leave tweens vulnerable. While 68 percent of parents surveyed said they monitored their child’s Internet behavior on mobile devices, the survey showed that only 1 in 5 (17 percent) actually use basic parental control features such as age appropriate web content filtering on smartphones, tablets and game consoles.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56493-cox-national-center-for-missing-exploited-children-keep-kids-safer-online
Each generation of tablet PCs and projectors seems to offer an ever-widening range of applications. Many of this year’s devices are cordless, water and impact resistant. This is great news for consumers. They are getting products that are more versatile and better at coping with the challenges of everyday life as well as extreme work environments.
BLACK+DECKER™ announces its new line of award-winning** SMARTECH™ Batteries, which use Bluetooth® Technology to connect to the new BLACK+DECKER Mobile App. The free BLACK+DECKER Mobile App has three components: My Products, Messages, and Projects. Combined with the new SMARTECH™ Battery USB charging feature, the app and batteries connect tools with technology to enhance the DIY experience.
The BLACK+DECKER Mobile App links with SMARTECH™ Batteries to provide a variety of functions. In the My Products section of the app, users can not only view a list of their connected batteries, but they can also select and interact directly with an individual battery when in range. From there, users can access four key functions: enable or disable the battery, view the percent of the battery’s remaining charge, turn on the locate feature to find a missing battery, or activate the battery’s integrated USB port. When activated, this port can power external devices, such as tablets and phones, connected via USB.
To view the multimedia release go to:
http://www.multivu.com/players/English/7517854-black-decker-smartech-bluetooth/
Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States beginning June 11.
BELVIQ was approved by the U.S. Food and Drug Administration on June 27, 2012 to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m² or greater (obese), or BMI of 27 kg/m² or greater (overweight) with at least one weight-related medical condition such as high blood pressure, high cholesterol, or type 2 diabetes. It is not known if BELVIQ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products, nor is it known if BELVIQ changes your risk of heart problems or stroke, or of death due to heart problems or stroke.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60316-eisai-belviq-civ-chronic-weight-management-tablets-for-overweight-adults
Bayer HealthCare’s Consumer Care division announced today the introduction of Bayer® Advanced Aspirin, the next generation of aspirin for pain relief. Using the patent-pending Pro-Release™ Technology, Bayer Advanced Aspirin is clinically proven to relieve tough pain twice as fast as previous Bayer® Aspirin tablets.
With the introduction of aspirin in 1899, Bayer offered one of the first widely accessible analgesics, or pain relievers, to consumers. Today, Bayer's overall global Aspirin business continues to grow, and had double-digit, year-on-year sales growth in Q1 2011. Yet, while Bayer continues to be a leader in the category, for many U.S. consumers, Bayer Aspirin is primarily synonymous with cardiovascular use. Now, through a combination of technological innovation and rich analgesic heritage, Bayer is introducing a new standard in aspirin for tough pain relief with Bayer Advanced Aspirin.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bayer/50414/
